The 2023-2028 World Outlook for Respiratory Diagnostics for Tuberculosis

The 2023-2028 World Outlook for Respiratory Diagnostics for Tuberculosis

This study covers the world outlook for respiratory diagnostics for tuberculosis across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

This study covers respiratory diagnostics for tuberculosis as defined by the North American Industrial Classification system or NAICS (pronounced "nakes").

The NAICS code for respiratory diagnostics for tuberculosis is 3254121176. It is for this definition that aggregate latent demand estimates are derived. Respiratory diagnostics for tuberculosis is specifically defined as follows:

3254121176 Anti neoplastic agents, including busulfan, chlorambucil, cyclophosphamide, vinscristine and antimetabolites (folic acid, purine, and glutamine antagonists)